Physician profile
Patrick P Mchugh
NPI 1881823987
$1,603.48
in general payments reported to CMS, 2019-2025
16 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.07 · 2020: $13.58 · 2021: $94.67 · 2022: $213 · 2023: $398 · 2024: $403 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,239 · Education: $3.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,238.59 |
| Education | $3.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $446.72 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $407.62 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $178.98 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $108.05 | 2022-2025 | Jynarque |
| Amgen INC. | $105.60 | 2024-2025 | Tavneos, Krystexxa, Uplizna |
| Mallinckrodt Hospital Products INC. | $60.60 | 2021-2023 | Acthar |
| Fresenius USA Marketing, INC. | $52.74 | 2021-2025 | Velphoro |
| Vifor Pharma, INC. | $39.14 | 2021-2023 | Veltassa, Korsuva |
| Calliditas Therapeutics US INC. | $38.46 | 2023 | Tarpeyo |
| Travere Therapeutics, INC. | $32.14 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $30.81 | 2022-2025 | Gattex |
| Horizon Therapeutics Plc | $26.52 | 2023 | Krystexxa |
| Mallinckrodt Enterprises LLC | $22.48 | 2019 | |
| Glaxosmithkline, LLC. | $20.35 | 2025 | Arexvy, Shingrix |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Opko Pharmaceuticals, LLC | $13.58 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Mchugh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.